ATHX 105

Drug Profile

ATHX 105

Alternative Names: ATHX-105

Latest Information Update: 17 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Athersys
  • Class Obesity therapies; Small molecules
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 07 May 2009 Suspended - Phase-I for Obesity in United Kingdom (PO)
  • 23 Sep 2008 Athersys provides update on ATHX 105 development plans
  • 23 Sep 2008 Safety and pharmacokinetics data from a phase I study of a modified release formulation of ATHX 105 released by Athersys
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top